Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. "The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to .

KRChoksey increased Accumulate price target of Dr. Reddy's Laboratories Ltd. to 1324.0 on 13 May, 2025.

Dr. Reddy's Laboratories Ltd.

15 Apr 2025

1251.20

0.24%

Dr. Reddy's Share Price Rises 3% As Firm Dismisses Report On Job Cuts

NDTV Profit

The pharma major called a Business Standard report on senior-level exits and cost trimming factually incorrect'.

Dr. Reddy's Laboratories Ltd. is trading below its 200 day SMA of 1257.6

Dr Reddy's Denies Plans To Implement 25% Workforce Cost Reduction

NDTV Profit | 14 Apr 2025 1 more

Dr. Reddy's Laboratories Ltd.

09 Apr 2025

1251.20

0.24%

US tariffs on Pharma: Dr Reddy's to Sun Pharmacan Indian drugmakers escape Trump's tariff tantrums?

livemint

US tariffs on Pharma: India currently levies up to 10% import duties on drugs imported from the US with several drugs having lower duty of 5% while around 150 drugs are exempted from duties.

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

09 Apr 2025

1251.20

0.24%

Kyndryl partners with Dr Reddy's to automate IT ops with AI-powered platform

Business Line

The initiative will implement a Zero Touch IT Operations model using Kyndryl's Dual Model IT Ops framework, targeting a 60% reduction in manual interventions

KRChoksey increased Accumulate price target of Dr. Reddy's Laboratories Ltd. to 1324.0 on 13 May, 2025.

Dr. Reddy's Laboratories Ltd.

07 Apr 2025

1251.20

0.24%

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

Business Standard

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

05 Apr 2025

1251.20

0.24%

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Business Standard

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Dr. Reddy's Laboratories Ltd. is trading above its 150 day SMA of 1226.0

Dr. Reddy's faces 2,395 crore tax reassessment notice

Business Line | 05 Apr 2025

Dr. Reddy's Laboratories Ltd.

26 Mar 2025

1251.20

0.24%

Bio-Thera, Dr. Reddy's partner for biosimilar expansion in Southeast Asia

Business Standard

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr Reddy's inks exclusive commercialisation pact on biosimilars for Southeast Asia

Business Line | 26 Mar 2025

Dr. Reddy's Laboratories Ltd.

13 Mar 2025

1251.20

0.24%

Dr Reddy's Recalls Epilepsy Drug Levetiracetam In US Over Mislabelling Concerns

NDTV Profit

The pharmaceutical company issued a risk statement that the patients who are administered the mislabelled product will likely experience serious side effects.

KRChoksey increased Accumulate price target of Dr. Reddy's Laboratories Ltd. to 1324.0 on 13 May, 2025.

Dr. Reddy's recalls Levetiracetam Sodium Chloride Injection in US market

Business Line | 13 Mar 2025

Dr. Reddy's Laboratories Ltd.

25 Feb 2025

1251.20

0.24%

Dr Reddy's Laboratories' Facility Gets FDA EIR With Voluntary-Action-Indicated Classification

NDTV Profit

The VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Dr. Reddy's Laboratories Ltd. is trading below its 200 day SMA of 1257.6

Indian drugmakers to stay competitive despite US tariff plans: Dr Reddy's

Business Standard | 25 Feb 2025

Is Dr. Reddy's Laboratories Ltd. worth buying?

508 Votes:

Buy 78.15%

Sell 12.2%

Hold 9.65%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf